drugset / Trial / NCT03232918

Oxytocin and Fetal Heart Rate Changes

NCT03232918

Phase 4 Recruiting 730 enrolled Unyime Ituk
RandomizedParallel-groupTriple-blindTreatment

Summary

The reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. This variability may be due to fluid and oxytocin management prior to and during the initiation of neuraxial analgesia. The study hypothesis is that decreasing the oxytocin infusion rate by 50 % prior to initiation of combined spinal epidural analgesia will cause a reduction in the incidence of adverse fetal heart rate changes.

Timeline

Start
2019-02-20
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide